Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572299 · ClinicalTrials.gov registry record
Glucocorticoids Promote Osteoclast Survival
A clinical trial, sponsored by University of Arkansas.
- Terminated
- Registry status
- 3
- Enrollment target
NCT00572299 is a clinical trial that was terminated before completion, run by University of Arkansas. The registered enrollment target is 3 participants.
The verdict
NCT00572299 was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the difference in response to bisphosphonate therapy in patients receiving excess glucocorticoids compared to patients with postmenopausal or male osteoporosis. Bisphosphonates are approved by the FDA for the treatment of postmenopausal women and osteoporotic men who are at high risk of fracture and in men and women with excess glucocorticoid administration.
Interventions
- DRUG alendronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2004-01 |
| Est. Completion | 2010-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572299
The ClinicalTrials.gov registry entry for NCT00572299 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alendronate is the first listed.
NCT00572299 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00572299 about?
NCT00572299 is a clinical study titled "Glucocorticoids Promote Osteoclast Survival". The purpose of this study is to determine the difference in response to bisphosphonate therapy in patients receiving excess glucocorticoids compared to patients with postmenopausal or male osteoporosis. Bisphosphonates are approved by the FDA for the treatment of postmenopausal women and osteoporoti...
What is the current status of trial NCT00572299?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2004-01. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00572299?
The interventions under investigation include: alendronate (DRUG).
Who is sponsoring clinical trial NCT00572299?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.